Poulton Stuart

SEC source: 0001193125-26-326290 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,632

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-226697 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,821

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-226697 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 95,224

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2024 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 XPORT-EC-042 trial, as certified by the issuer's Compensation Committee on May 13, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on May 13, 2026.

SEC source: 0001942597-26-000003 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,328

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-059332 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,429

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-26-035655 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 99,807

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on January 31, 2027, with the remaining 50% vesting on January 31, 2028.

SEC source: 0001193125-25-241484 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,392

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest 100% on December 31, 2026.

SEC source: 0001193125-25-205046 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,710

F2 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001193125-25-205046 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,111

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the clinical milestone for complete enrollment in the Company's Phase 3 SENTRY trial, as certified by the issuer's Compensation Committee on September 12, 2025. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on September 12, 2025.

SEC source: 0000950170-25-100373 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,223

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-25-034723 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,414

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $6.14 to $6.31, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-25-032309 · ownership.xml · derivative · entry 4

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,166

Underlying: Common Stock · 9,166 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · derivative · entry 3

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2035-02-27

F2 · derivative.exercise_price: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F4 · derivative.exercise_date: This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.

F2 · derivative.underlying_shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,962

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F3 · shares: Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-032309 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,379

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.

F2 · shares: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

F2 · balance_after: Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.

SEC source: 0000950170-25-023192 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 320,714

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-088589 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,628

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025192 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 329,511

F3 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of performance-based restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-025192 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 335,666

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.18, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

SEC source: 0000950170-24-023293 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,977

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2025.

SEC source: 0000950170-24-017237 · ownership.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,772

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-017237 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,871

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0000950170-24-007610 · ownership.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,619

F1 · shares: Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of a certain clinical milestone, as certified by the issuer's compensation committee on January 24, 2024. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs will vest on February 28, 2024, the first anniversary of the grant date, subject to continued employment through such vesting date.

SEC source: 0001209191-23-044040 · doc4.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 156,286

F1 · kind: This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-014872 · doc4.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 159,131

F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 3

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,131

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 2

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,327

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.

SEC source: 0001209191-23-010509 · doc4.xml · nonDerivative · entry 1

Poulton Stuart · CIK 0001942597 · EVP, Chief Development Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,335

F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.